Model-based simulations predict that switching from semaglutide or dulaglutide to tirzepatide yields additional HbA1c reduction and weight loss, with the magnitude depending on the prior GLP-1RA dose.
Additional improvements predictedModel simulations show further HbA1c and weight reductions when switching from GLP-1RAs to tirzepatide
What the researchers found
Model-based simulations predict additional HbA1c and body weight reductions when switching from semaglutide or dulaglutide to tirzepatide, with magnitude depending on prior therapy and dose.
Why it matters
Many patients on GLP-1 RAs may benefit from switching to tirzepatide, but clinicians lack data on expected outcomes during the transition. These models provide practical guidance for a common clinical decision — when and what to expect when upgrading therapy.
The numbers in context
Models built from SUSTAIN 1-10, AWARD-11, and SURPASS 1-5 trial data; simulated switching from once-weekly semaglutide or dulaglutide to tirzepatide.
How the study worked
Pharmacometric modeling using validated models developed from SUSTAIN 1-10 (semaglutide), AWARD-11 (dulaglutide), and SURPASS 1-5 (tirzepatide) phase 3 trial data. Simulated switching scenarios with efficacy time-course projections.
Who was studied
Simulated type 2 diabetes patients switching between incretin-based therapies
What this study cannot tell us
Model-based simulation, not real clinical trial data. Predictions depend on model assumptions and may not capture all real-world factors (adherence, comorbidities, concomitant medications). No safety outcome modeling. Models derived from trial populations that may not represent all patients.
How to read the evidence
Moderate evidence — validated pharmacometric models based on robust phase 3 trial data, but predictions require confirmation with real-world switching studies.
When this study was published
Published in 2024. Timely as tirzepatide adoption increases and therapy switching becomes more common.
The bigger picture
As the incretin drug class expands, treatment switching will become routine. These pharmacometric models establish a framework for predicting outcomes during therapy transitions — information that's critical for shared decision-making between clinicians and patients.
Questions still open
- Do real-world switching outcomes match these model predictions?
- Is there a threshold dose of prior GLP-1RA below which switching to tirzepatide provides the most benefit?
- How should the transition period be managed to minimize GI side effects?
Common questions
What happens if I switch from semaglutide to tirzepatide?
Why would someone switch from one diabetes injection to another?
Read the original research
Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Current medical research and opinion, 40(4), 567-574
Citation
Urva, Shweta; Levine, Joshua A; Schneck, Karen; Tang, Cheng Cai. (2024). Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.. Current medical research and opinion, 40(4), 567-574. https://doi.org/10.1080/03007995.2024.2322072